APOE and Alzheimer disease: The detection of tau pathology in a relatively late stage and in a more mature (insoluble) conformation with PET is in line with its strong cognitive and neurodegenerative correlates (i.e. markers of disease progression), while the detection of early abnormalities in tau metabolism with CSF and plasma is consistent with their strong associations with early indicators of AD‐like ageing and APOE ɛ4 and Aβ positivity.